General MedicationsORALStandard
SEROMYCIN
CYCLOSERINE
Standard Dose
250MG
Max Dose
Refer to approved labeling
Primary Use
Review priority: UNKNOWN Marketing status: Prescription
Summary
Approval overview SEROMYCIN is listed in Drugs@FDA under application 060593 (ANDA).
Review priority: UNKNOWN Marketing status: Prescription Active ingredient CYCLOSERINE Form and strength CAPSULE;ORAL - 250MG Sponsor SANALUZ Submission history Latest submission status date: 2023-03-03 00:00:00.
Structured Monograph
Clinical summary
Approval overview SEROMYCIN is listed in Drugs@FDA under application 060593 (ANDA). Review priority: UNKNOWN Marketing status: Prescription Active ingredient CYCLOSERINE Form and strength CAPSULE;ORAL - 250MG Sponsor SANALUZ Submission history Latest submission status date: 2023-03-03 00:00:00. Submission type: SUPPL.
Monitoring
- • Marketing status: Prescription
- • Review priority: UNKNOWN
Interaction Notes
- No interaction notes stored yet.